FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "Evidence",
  "id": "236969",
  "meta": {
    "versionId": "70",
    "lastUpdated": "2025-10-07T17:12:54.639Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
    ]
  },
  "language": "en",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "url": "https://fevir.net/resources/Evidence/236969",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "236969",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "type": {
        "text": "outcomeId"
      },
      "system": "https://app.magicapp.org/#/guidelines",
      "value": "313961"
    },
    {
      "type": {
        "text": "picoId"
      },
      "system": "https://app.magicapp.org/#/guidelines",
      "value": "85798"
    },
    {
      "type": {
        "text": "sectionId"
      },
      "system": "https://app.magicapp.org/#/guidelines",
      "value": "73215"
    }
  ],
  "name": "Heart_failure_from_MAGICapp_313961",
  "title": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
  "citeAs": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236969. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236969. Computable resource at: https://fevir.net/resources/Evidence/236969#json.",
  "status": "active",
  "author": [
    {
      "name": "Computable Publishing®: MAGIC-to-FEvIR Converter"
    }
  ],
  "publisher": "Computable Publishing LLC",
  "contact": [
    {
      "telecom": [
        {
          "system": "email",
          "value": "support@computablepublishing.com"
        }
      ]
    }
  ],
  "useContext": [
    {
      "code": {
        "system": "https://fevir.net/resources/CodeSystem/179423",
        "code": "evidence-communication",
        "display": "Evidence Communication"
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "ComparativeEvidence",
            "display": "ComparativeEvidence"
          }
        ]
      }
    }
  ],
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "relatesTo": [
    {
      "type": "part-of",
      "targetReference": {
        "type": "Composition",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-conversion-report",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
      }
    }
  ],
  "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "assertion": "SGLT2 inhibitors reduce the risk of heart failure compared with GLP-1 receptor agonists.",
  "variableDefinition": [
    {
      "description": "Adults with type 2 diabetes",
      "variableRole": "population",
      "observed": {
        "reference": "Group/236947",
        "type": "Group",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-population-group-85394-85798",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "Adults with type 2 diabetes and CVD and CKD"
      }
    },
    {
      "description": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA",
      "variableRole": "exposure",
      "comparatorCategory": "GLP-1 RA",
      "observed": {
        "reference": "EvidenceVariable/236950",
        "type": "EvidenceVariable",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-group-assignment-85394-85798",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"
      }
    },
    {
      "description": "Heart failure",
      "variableRole": "outcome",
      "observed": {
        "reference": "EvidenceVariable/236968",
        "type": "EvidenceVariable",
        "identifier": {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "MAGIC-5288-j1Wqrn-313961",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        },
        "display": "Hospital admission for heart failure"
      }
    }
  ],
  "synthesisType": [
    {
      "text": "SYSTEMATIC_REVIEW"
    }
  ],
  "studyDesign": [
    {
      "text": "NOTSET"
    }
  ],
  "statistic": [
    {
      "description": "Risk Difference -4.8% (CI95 -6.6% to -2.7%)",
      "statisticType": {
        "coding": [
          {
            "system": "https://fevir.net/sevco",
            "code": "STATO:0000424",
            "display": "risk difference"
          }
        ]
      },
      "quantity": {
        "value": -0.048
      },
      "attributeEstimate": [
        {
          "type": {
            "text": "CI95"
          },
          "range": {
            "low": {
              "value": -0.066
            },
            "high": {
              "value": -0.027
            }
          }
        }
      ]
    },
    {
      "description": "OR 0.74 (CI95 0.65 to 0.85)",
      "statisticType": {
        "coding": [
          {
            "system": "https://fevir.net/sevco",
            "code": "STATO:0000182",
            "display": "odds ratio"
          }
        ]
      },
      "quantity": {
        "value": 0.74
      },
      "attributeEstimate": [
        {
          "type": {
            "text": "CI95"
          },
          "range": {
            "low": {
              "value": 0.65
            },
            "high": {
              "value": 0.85
            }
          }
        }
      ]
    }
  ],
  "certainty": [
    {
      "type": {
        "coding": [
          {
            "system": "http://hl7.org/fhir/certainty-type",
            "code": "Overall",
            "display": "Overall certainty"
          }
        ]
      },
      "rating": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/27834",
            "code": "RJCS-2003",
            "display": "High certainty"
          }
        ]
      },
      "subcomponent": [
        {
          "type": {
            "text": "Risk of Bias"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Inconsistency"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Indirectness"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Imprecision"
          },
          "rating": {
            "text": "NOTSET"
          }
        },
        {
          "type": {
            "text": "Publication Bias"
          },
          "rating": {
            "text": "NOTSET"
          }
        }
      ]
    }
  ]
}